APO Research
Talk to an analyst

APO RESEARCH · REPORT

Armodafinil

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Armodafinil Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchArmodafinil Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Armodafinil Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Armodafinil Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Armodafinil Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Armodafinil Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Armodafinil market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Armodafinil is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Armodafinil is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Armodafinil is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Armodafinil market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Armodafinil market include Apotex, Aurobindo, Lupin, Natco Pharma, Mylan, Sandoz and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Armodafinil market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Armodafinil and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Armodafinil revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Armodafinil market.

Armodafinil Segment by Company

Apotex

Aurobindo

Lupin

Natco Pharma

Mylan

Sandoz

Teva

Armodafinil Segment by Type

50 mg Tablets

250 mg Tablets

200 mg Tablets

150 mg Tablets

Armodafinil Segment by Application

Obstructive Sleep Apnea (OSA) and Narcolepsy

Patients with Severe Hepatic Impairment

Shift Work Disorder (SWD)

Geriatric Patients

Armodafinil Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Armodafinil status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Armodafinil key companies, revenue, market share, and recent developments.

3. To split the Armodafinil breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Armodafinil market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Armodafinil significant trends, drivers, influence factors in global and regions.

6. To analyze Armodafinil competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Armodafinil market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Armodafinil and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Armodafinil.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Armodafinil industry.

Chapter 3: Detailed analysis of Armodafinil company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Armodafinil in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Armodafinil in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Armodafinil Industry Trends Table 2. Armodafinil Industry Drivers Table 3. Armodafinil Industry Opportunities and Challenges Table 4. Armodafinil Industry Restraints Table 5. Global Armodafinil Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Armodafinil Revenue Share by Company (2021-2026) Table 7. Global Armodafinil Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Armodafinil Key Company Manufacturing Base & Headquarters Table 9. Global Armodafinil Company, Product Type & Application Table 10. Global Armodafinil Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Armodafinil by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 50 mg Tablets Table 15. Significant Companies of 250 mg Tablets Table 16. Significant Companies of 200 mg Tablets Table 17. Significant Companies of 150 mg Tablets Table 18. Global Armodafinil Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Armodafinil Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Armodafinil Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Armodafinil Sales Value Share by Type (2021-2026) Table 22. Global Armodafinil Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Obstructive Sleep Apnea (OSA) and Narcolepsy Table 24. Significant Companies of Patients with Severe Hepatic Impairment Table 25. Significant Companies of Shift Work Disorder (SWD) Table 26. Significant Companies of Geriatric Patients Table 27. Global Armodafinil Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Armodafinil Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Armodafinil Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Armodafinil Sales Value Share by Application (2021-2026) Table 31. Global Armodafinil Sales Value Share by Application (2027-2032) Table 32. Global Armodafinil Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Armodafinil Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Armodafinil Sales Value Share by Region (2021-2026) Table 35. Global Armodafinil Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Armodafinil Sales Value Share by Region (2027-2032) Table 37. Global Armodafinil Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Armodafinil Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Armodafinil Sales Value Market Share by Country (2021-2026) Table 40. Global Armodafinil Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Armodafinil Sales Value Market Share by Country (2027-2032) Table 42. Apotex Company Information Table 43. Apotex Business Overview Table 44. Apotex Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Apotex Armodafinil Product Portfolio Table 46. Apotex Recent Development Table 47. Aurobindo Company Information Table 48. Aurobindo Business Overview Table 49. Aurobindo Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Aurobindo Armodafinil Product Portfolio Table 51. Aurobindo Recent Development Table 52. Lupin Company Information Table 53. Lupin Business Overview Table 54. Lupin Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Lupin Armodafinil Product Portfolio Table 56. Lupin Recent Development Table 57. Natco Pharma Company Information Table 58. Natco Pharma Business Overview Table 59. Natco Pharma Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Natco Pharma Armodafinil Product Portfolio Table 61. Natco Pharma Recent Development Table 62. Mylan Company Information Table 63. Mylan Business Overview Table 64. Mylan Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Mylan Armodafinil Product Portfolio Table 66. Mylan Recent Development Table 67. Sandoz Company Information Table 68. Sandoz Business Overview Table 69. Sandoz Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sandoz Armodafinil Product Portfolio Table 71. Sandoz Recent Development Table 72. Teva Company Information Table 73. Teva Business Overview Table 74. Teva Armodafinil Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Armodafinil Product Portfolio Table 76. Teva Recent Development Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Armodafinil Product Image Figure 2. Global Armodafinil Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Armodafinil Market Size (2021-2032) & (US$ Million) Figure 4. Global Armodafinil Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 50 mg Tablets Image Figure 8. 250 mg Tablets Image Figure 9. 200 mg Tablets Image Figure 10. 150 mg Tablets Image Figure 11. Global Armodafinil Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Armodafinil Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Armodafinil Sales Value Share by Type (2021-2032) Figure 14. Obstructive Sleep Apnea (OSA) and Narcolepsy Image Figure 15. Patients with Severe Hepatic Impairment Image Figure 16. Shift Work Disorder (SWD) Image Figure 17. Geriatric Patients Image Figure 18. Global Armodafinil Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Armodafinil Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Armodafinil Sales Value Share by Application (2021-2032) Figure 21. Global Armodafinil Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Armodafinil Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Armodafinil Sales Value (2021-2032) & (US$ Million) Figure 24. North America Armodafinil Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Armodafinil Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Armodafinil Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Armodafinil Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Armodafinil Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Armodafinil Sales Value (2021-2032) & (US$ Million) Figure 30. South America Armodafinil Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Armodafinil Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Armodafinil Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Armodafinil Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Armodafinil Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Armodafinil Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • 50 mg Tablets
  • 250 mg Tablets
  • 200 mg Tablets
  • 150 mg Tablets
Applications
  • Obstructive Sleep Apnea (OSA) and Narcolepsy
  • Patients with Severe Hepatic Impairment
  • Shift Work Disorder (SWD)
  • Geriatric Patients
Companies covered
  • Apotex
  • Aurobindo
  • Lupin
  • Natco Pharma
  • Mylan
  • Sandoz
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Armodafinil Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Armodafinil Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Armodafinil Market Dynamics
  1. 2.1 Armodafinil Industry Trends
  2. 2.2 Armodafinil Industry Drivers
  3. 2.3 Armodafinil Industry Opportunities and Challenges
  4. 2.4 Armodafinil Industry Restraints
3 Armodafinil Market by Company
  1. 3.1 Global Armodafinil Company Revenue Ranking in 2025
  2. 3.2 Global Armodafinil Revenue by Company (2021-2026)
  3. 3.3 Global Armodafinil Company Ranking (2024-2026)
  4. 3.4 Global Armodafinil Company Manufacturing Base and Headquarters
  5. 3.5 Global Armodafinil Company Product Type and Application
  6. 3.6 Global Armodafinil Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Armodafinil Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Armodafinil Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Armodafinil Market by Type
  1. 4.1 Armodafinil Type Introduction
  2. 4.1.1 50 mg Tablets
  3. 4.1.2 250 mg Tablets
  4. 4.1.3 200 mg Tablets
  5. 4.1.4 150 mg Tablets
  6. 4.2 Global Armodafinil Sales Value by Type
  7. 4.2.1 Global Armodafinil Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Armodafinil Sales Value by Type (2021-2032)
  9. 4.2.3 Global Armodafinil Sales Value Share by Type (2021-2032)
5 Armodafinil Market by Application
  1. 5.1 Armodafinil Application Introduction
  2. 5.1.1 Obstructive Sleep Apnea (OSA) and Narcolepsy
  3. 5.1.2 Patients with Severe Hepatic Impairment
  4. 5.1.3 Shift Work Disorder (SWD)
  5. 5.1.4 Geriatric Patients
  6. 5.2 Global Armodafinil Sales Value by Application
  7. 5.2.1 Global Armodafinil Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Armodafinil Sales Value by Application (2021-2032)
  9. 5.2.3 Global Armodafinil Sales Value Share by Application (2021-2032)
6 Armodafinil Regional Value Analysis
  1. 6.1 Global Armodafinil Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Armodafinil Sales Value by Region (2021-2032)
  3. 6.2.1 Global Armodafinil Sales Value by Region: 2021-2026
  4. 6.2.2 Global Armodafinil Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Armodafinil Sales Value (2021-2032)
  7. 6.3.2 North America Armodafinil Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Armodafinil Sales Value (2021-2032)
  10. 6.4.2 Europe Armodafinil Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Armodafinil Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Armodafinil Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Armodafinil Sales Value (2021-2032)
  16. 6.6.2 South America Armodafinil Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Armodafinil Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Armodafinil Sales Value Share by Country, 2025 VS 2032
7 Armodafinil Country-level Value Analysis
  1. 7.1 Global Armodafinil Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Armodafinil Sales Value by Country (2021-2032)
  3. 7.2.1 Global Armodafinil Sales Value by Country (2021-2026)
  4. 7.2.2 Global Armodafinil Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Armodafinil Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Armodafinil Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Armodafinil Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Armodafinil Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Armodafinil Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Armodafinil Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Armodafinil Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Armodafinil Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Armodafinil Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Armodafinil Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Armodafinil Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Armodafinil Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Armodafinil Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Armodafinil Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Armodafinil Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Armodafinil Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Armodafinil Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Armodafinil Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Armodafinil Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Armodafinil Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Armodafinil Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Armodafinil Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Armodafinil Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Armodafinil Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Armodafinil Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Armodafinil Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Armodafinil Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Armodafinil Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Armodafinil Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Armodafinil Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Armodafinil Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Armodafinil Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Armodafinil Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Armodafinil Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Armodafinil Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Armodafinil Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Armodafinil Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Armodafinil Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Armodafinil Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Armodafinil Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Armodafinil Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Armodafinil Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Armodafinil Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Armodafinil Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Armodafinil Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Armodafinil Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Armodafinil Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Armodafinil Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Armodafinil Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Armodafinil Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Armodafinil Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Armodafinil Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Armodafinil Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Armodafinil Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Armodafinil Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Armodafinil Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Armodafinil Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Armodafinil Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Armodafinil Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Armodafinil Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Armodafinil Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Armodafinil Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Armodafinil Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Armodafinil Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Armodafinil Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Armodafinil Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Armodafinil Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Armodafinil Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Armodafinil Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Armodafinil Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Armodafinil Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Armodafinil Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Armodafinil Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Armodafinil Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Armodafinil Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Armodafinil Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Armodafinil Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Armodafinil Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Armodafinil Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Armodafinil Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Armodafinil Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Armodafinil Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Armodafinil Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Armodafinil Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Apotex
  2. 8.1.1 Apotex Company Information
  3. 8.1.2 Apotex Business Overview
  4. 8.1.3 Apotex Armodafinil Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Apotex Armodafinil Product Portfolio
  6. 8.1.5 Apotex Recent Developments
  7. 8.2 Aurobindo
  8. 8.2.1 Aurobindo Company Information
  9. 8.2.2 Aurobindo Business Overview
  10. 8.2.3 Aurobindo Armodafinil Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aurobindo Armodafinil Product Portfolio
  12. 8.2.5 Aurobindo Recent Developments
  13. 8.3 Lupin
  14. 8.3.1 Lupin Company Information
  15. 8.3.2 Lupin Business Overview
  16. 8.3.3 Lupin Armodafinil Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lupin Armodafinil Product Portfolio
  18. 8.3.5 Lupin Recent Developments
  19. 8.4 Natco Pharma
  20. 8.4.1 Natco Pharma Company Information
  21. 8.4.2 Natco Pharma Business Overview
  22. 8.4.3 Natco Pharma Armodafinil Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Natco Pharma Armodafinil Product Portfolio
  24. 8.4.5 Natco Pharma Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Armodafinil Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Armodafinil Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz Armodafinil Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz Armodafinil Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Armodafinil Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Armodafinil Product Portfolio
  42. 8.7.5 Teva Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst